On the other hand, IL-1B has been found to promote the absorption of oxidized LDL in human glomerular mesangial cells with the prominent participation of LOX-1, suggesting that a therapy to lower LOX-1 levels is a promising therapy to treat glomerulosclerosis that is related to renal failure in young and adult patients [50]. The gene discussed is OLR1; the disease is acute kidney injury.